1. Market Research
  2. > Pharmaceutical Market Trends
Global Smart Inhalers Market Size, Share & Industry Trends Analysis Report By Product, By Disease Indication, By Distribution Channel, By Regional Outlook and Forecast, 2021 - 2027

Global Smart Inhalers Market Size, Share & Industry Trends Analysis Report By Product, By Disease Indication, By Distribution Channel, By Regional Outlook and Forecast, 2021 - 2027

  • March 2022
  • 205 pages
  • ID: 6273382
  • Format: PDF
  • KBV Research

Summary

Table of Contents

The Global Smart Inhalers Market size is expected to reach $414.4 million by 2027, rising at a market growth of 24.9% CAGR during the forecast period.

Smart inhalers are inhalation devices that deliver a range of medications. Inhalers contain anticholinergic, glucocorticoids, insulin, and beta-agonists, which are used to treat and prevent respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). When sensors are placed as a clip to inhalers to monitor the proper dose per intake and the technique used for inhaling the drug, these inhalers are referred to as smart inhalers. The sensor’s data is shared with the patient and healthcare practitioners in order to track inhaler usage. The monitored data is then exchanged with their mobile apps via an internet platform using Bluetooth technology, and electronic health records (EHR) or electronic medical records (EMR) are preserved as a result.

Some smart inhalers have sensors that can identify whether a person is in a polluted or pollen-filled environment, give useful reminders, and indicate if an individual’s inhaler technique needs to be reviewed. Individuals do not need to maintain their own records because all inhalers are intended to automatically track how often they are used.

Indoor air pollution in households in underdeveloped and developing countries is becoming a more widespread problem with an increase in the population of these countries. Respiratory problems such as COPD and asthma are more common in people who live in substandard housing and neighborhoods. Inhalation of particles occurs when kerosene lights and portable stoves are used for heating and cooking. Furthermore, rising tobacco consumption among both men and women in high-income nations, as well as increased risk of indoor air pollution, are projected to raise the prevalence of respiratory disease in both men and women. Smoking, biomass fuel for heating and cooking, and poor ventilation are all sources of indoor pollution in low-income countries. As a result, an increase in indoor pollution is expected to lead to an increase in asthma and COPD cases, driving the market.

COVID-19 Impact

The outbreak of the COVID-19 pandemic has impacted various sectors of the business domain. The imposition of various restrictions like lockdown, ban on cross border travelling, social distancing norm, temporary ban on manufacturing units and ban on imports & exports, have disrupted the supply chain of various goods or products across the world. In addition, the burden on healthcare sector has increased due to the pandemic. The COVID-19 pandemic is expected to have a favorable impact on the market for smart inhalers. A large number of clinics and hospitals around the world have been reconfigured to boost hospital capacity for COVID-19 patients. Due to the substantial increase in COVID-19 cases, non-essential procedures may face a backlog.

Market Growth Factors

Increase in The Incidence of Chronic Respiratory Diseases

Asthma is the name of a chronic pulmonary disease by which both children and adults can be affected. Due to inflammation and tightening of the muscles around the tiny airways, the air channels in the lungs shrink. Asthma patients suffer from symptoms such as coughing, wheezing, shortness of breath, and chest tightness. These sensations are transitional, however, importantly, these symptoms worsen at night and during physical workouts. Asthma symptoms can be exacerbated by other common external and internal factors. Viral infections (colds), dust, smoke, fumes, changes in the weather, grass and tree pollen, animal fur and feathers, harsh soaps, and perfume are all potential triggers the intensity of the effects of the triggers that may vary from person to person.

Smart Inhalers are More Efficient Than Regular Inhalers

Smart inhalers are not only simply inhalers but any electronic devices capable of sharing data and tracking records. With the use of Bluetooth, digital inhalers may be connected to smartphones, allowing for dosing reminders and dose monitoring. Additionally, these devices have patient education tools that help to reduce dosing errors, resulting in lower hospitalization and treatment costs. The number of doctor visits of patients who utilized these types of inhalers fell dramatically. Increasing research and development about smart inhalers are likely to make them more effective and efficient, thus increasing their demand in the market.

Market Restraining Factors

Smart Inhalers are Expensive

A smart inhaler is priced at around $99 on average. This varies based on the brand and the capabilities it offers. Naturally, the more sophisticated the capabilities, the more expensive they are. The same may be said for the cost of smart inhalers, which have sensors built into the device. Only specific medications and inhalers are authorized for use with some smart inhalers. As a result, double-checking the manufacturer’s website or asking the pharmacist for further information about the inhaler, asthma treatments, and mobile device compatibility becomes essential. Purchasing medications can be costly, and purchasing equipment or devices to help manage the disease implies further expenses.

Product Outlook

Based on Product, the market is segmented into Metered Dose Inhalers (MDI’s), and Dry Powdered Inhalers (DPIs). The dry powder inhaler (DPI) segment witnessed a significant revenue share in the smart inhalers market in 2020. A dry powder inhaler (DPI), which is a handheld device, can be used to administer certain drugs in the form of a dry powder. As users inhale through it, a DPI delivers medication to their lungs. There are no propellants or other substances in it; only the medication, which is propelling the growth of the segment.

Disease Indication Outlook

Based on Disease Indication, the market is segmented into Asthma, and Chronic Obstructive Pulmonary Disease (COPD). The asthma segment garnered the largest revenue share in the smart inhalers market in 2020. This is because of the sheer growing incidence of persons suffering from asthma. During the next few years, the segmental expansion will be fueled by a growing patient pool. In the United States, for example, 1 in 13 people have asthma, according to the Centers for Disease Control and Prevention (CDC). It is estimated that over 25 million Americans suffer from asthma. As a result, the rising prevalence of asthma, combined with rising public knowledge about the disease’s risk, will drive the adoption of the smart inhalers market over the forecast period. The increase in demand for smart inhalers is likely to continue to do so during the forecast period.

Distribution Channel Outlook

Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies. The retail pharmacies segment observed a significant revenue share in the smart inhalers market in 2020. The increasing number of retail pharmacies around the world is responsible for the high increase. Furthermore, numerous smart inhaler manufacturers are stepping up their attempts to form partnerships with retail pharmacies in order to begin selling these devices over-the-counter, which will help the market grow even faster. Another key factor driving growth is the increasing number of FDA approvals for over-the-counter sales of digital inhalers. Adherium, for example, received FDA approval for over-the-counter sales of their digital inhaler sensor for AstraZeneca’s asthma inhalation device in April 2018.

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. The North American segment acquired the largest revenue share of the smart inhalers market in 2020. This is due to improved healthcare infrastructure and services, a higher prevalence of asthma and COPD patients, the adoption of technologically sophisticated therapies, and increased healthcare expenditure in the region. People in North America tend to be more affluent than the population of the rest of the world and thus, the increasing adoption of smart inhalers in the region has not come to anyone’s surprise.

The major strategies followed by the market participants are Partnerships. Based on the Analysis presented in the Cardinal matrix; Novartis AG is the forerunners in the Smart Inhalers Market. Companies such as AstraZeneca, Inc., GlaxoSmithKline Plc, Teva Pharmaceutical Industries Ltd. are some of the key innovators in the Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Adherium Limited, Aptar Group Inc. (Cohero Health Inc.), AstraZeneca, Inc., Cognita Labs, LLC, GlaxoSmithKline Plc, Novartis AG, OPKO Health, Inc., Philip Morris International, Inc. (Vectura Group Plc), Resmed, Inc. (Propeller Health), and Teva Pharmaceutical Industries Ltd.

Strategies Deployed in Smart Inhalers Market

Feb-2022: Aptar Pharma introduced HeroTracker Sense, a novel digital respiratory health solution. The device is designed to enhance the health of patients across the world suffering from chronic respiratory diseases such as COPD, Cystic Fibrosis, asthma, and other respiratory conditions caused by COVID-19. Additionally, the device tracks their MDI usage and expedites enhanced adherence to their prescribed treatment.

Sep-2020: Teva Respiratory introduced ArmonAir Digihaler inhalation powder and AirDuo Digihaler inhalation powder. These two digital inhalers help in managing asthma inhalers among patients.

Jul-2020: Novartis received European Commission approval for glycopyrronium bromide, Enerzair Breezhaler, mometasone furoate, and indacaterol acetate for the treatment of asthma. Through this approval, the drugs provide precaution treatment in adult patients not appropriately controlled with a management combination of a long-acting beta2 agonist as well as a high-dose of an inhaled corticosteroid who experienced one or more asthma worsening in the previous year.

Apr-2020: Aptar teamed up with Sonmol, a leading Chinese digital respiratory therapeutics company. Under this collaboration, the companies focused on delivering connected digital platforms and drug delivery devices for chronic obstructive pulmonary and asthma disease. Moreover, this collaboration aimed to develop digital services and therapies platforms targeting respiratory and other diseases.

Jan-2020: Cognita Labs received the FDA approval for CapMedic, a smart inhaler cap. The device alerts patients to utilize inhalers in the right way. Additionally, Developers believe the feedback mechanism differentiates the device from other smart inhalers.

Jan-2020: Aptar Pharma joined hands with Lupin Limited, an Indian multinational pharmaceutical company. Together, the companies aimed to introduce India’s first linked device for metered-dose inhalers called ADHERO. The smart device is developed to help patients with chronic respiratory diseases to track MDI utilization and facilitate enhanced attachment to their prescribed therapy.

Aug-2019: Adherium came into partnership with Summatix, a medical informatics company. Under this partnership, the companies empower doctors to improve the health of patients with chronic obstructive pulmonary and asthma diseases. Additionally, the Adherium post-reconstruction business model improves its platform abilities and sensor development by approaching and collaborating with dominant development houses to focus on insights on how data, and its application, would influence the practice of medicine.

Jul-2019: ResMed took over Propeller Health, a digital therapeutics company providing connected health solutions. Through this partnership, Propeller’s digital solutions strengthen ResMed’s large portfolio of products that can treat millions of people at multiple stages of their COPD and other chronic diseases, all aimed at enhancing people’s condition of life, while minimizing the effects of these hospitalizations, diseases, and the overall price of healthcare.

Aug-2018: Adherium introduced the Hailie solution in the U.S. The Food and Drug Administration approved that Hailie assists COPD and asthma patients to approach better precaution through a consistent digital experience that includes a smartphone app, available on both Android and iOS, along with a sensor that adheres to the patient’s prescription inhaler medication.

Sep-2017: Adherium received the FDA approval for clearance for its new SmartTouch for Symbicort, inhaler monitoring technology for AstraZeneca’s Symbicort aerosol inhaler. Through this approval, Symbicort equipped into patient’s inhaler to monitor and boost medication adherence as part of a self-administration plan.

Sep-2017: GlaxoSmithKline expanded its partnership with Propeller Health, a mobile platform that offers sensors, mobile apps, analytics, and services to support respiratory health management. Together, the companies aimed to design digital solutions for asthma and chronic obstructive pulmonary disorder.

Jan-2017: AstraZeneca received the FDA approval for Symbicort Inhalation Aerosol 80/4.5 micrograms. The medicine is introduced for the treatment of asthma in pediatric patients from age six up to 12 years. Additionally, Symbicort’s FDA approval was based on the CHASE clinical trial program, including the CHASE 3 Phase III trial.

Scope of the Study

Market Segments covered in the Report:

By Product

• Metered Dose Inhalers (MDI’s)

• Dry Powdered Inhalers (DPIs)

By Disease Indication

• Asthma

• Chronic Obstructive Pulmonary Disease (COPD)

By Distribution Channel

• Hospitals Pharmacies

• Retail Pharmacies

• Online Pharmacies

By Geography

• North America

o US

o Canada

o Mexico

o Rest of North America

• Europe

o Germany

o UK

o France

o Russia

o Spain

o Italy

o Rest of Europe

• Asia Pacific

o China

o Japan

o India

o South Korea

o Singapore

o Malaysia

o Rest of Asia Pacific

• LAMEA

o Brazil

o Argentina

o UAE

o Saudi Arabia

o South Africa

o Nigeria

o Rest of LAMEA

Companies Profiled

• Adherium Limited

• Aptar Group Inc. (Cohero Health Inc.)

• AstraZeneca, Inc.

• Cognita Labs, LLC

• GlaxoSmithKline Plc

• Novartis AG

• OPKO Health, Inc.

• Philip Morris International, Inc. (Vectura Group Plc)

• Resmed, Inc. (Propeller Health)

• Teva Pharmaceutical Industries Ltd.

Unique Offerings

• Exhaustive coverage

• Highest number of market tables and figures

• Subscription based model available

• Guaranteed best price

• Assured post sales research support with 10% customization free

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

mRNA Platform Market Research Report by Indication, Usability, mRNA Type, End-User, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

  • $ 2949
  • July 2022
  • 144 pages

mRNA Platform Market Research Report by Indication (Autoimmune Diseases, Cancer, and Infectious Dieses), Usability, mRNA Type, End-User, State (California, New York, and Illinois) - United States Forecast ...

  • United States
  • Autoimmune Disease
  • Marketing Research
  • Industry analysis

ref:plp2022

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on